Participants may not have had history of abdominal fistula or gastrointestinal perforation within the past months Gastrointestinal perforation or fistula in the months prior to randomization unless underlying risk has been resolved (e.g., through surgical resection or repair) History of abdominal fistula or gastrointestinal perforation within months prior to day History of gastrointestinal perforation and/or fistulae within months prior to initiation of study treatment; History of known risks factors for bowel perforation History of gastrointestinal perforation within last months. history of abdominal fistula or gastrointestinal perforation History of gastrointestinal perforation and/or fistulae within months prior to enrollment No history of gastrointestinal fistula or gastrointestinal perforation < days of registration History of upper GI bleeding, ulceration or perforation within months before the first dose of defactinib. History of abdominal fistula or gastrointestinal perforation within months prior to registration At risk of bowel perforation No myocardial infarction, gastrointestinal (GI) perforation/fistula, intraabdominal abscess, cerebrovascular accidents within six months prior to study entry Prior history of gastrointestinal diverticulitis, perforation, or abscess. History of prior gastrointestinal fistula and/or perforation History of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past years; patients with ulceration, bleeding or perforation in the lower bowel are not excluded Any history of gastrointestinal (GI) perforation, history of intra-abdominal abscess within months prior to starting treatment, or history of abdominal fistula unless the fistula history meets all the following: (a) the fistula was surgically repaired, (b) there has been no evidence of fistula for at least months prior to starting treatment, (c) patient is deemed to be at low risk of recurrent fistula, and (d) the case must be discussed with the study PI History of gastrointestinal fistula, hemorrhage, perforation or peptic ulcer disease History of gastrointestinal perforation or fistula in the months prior to study treatment, or while previously on antiangiogenic therapy, unless underlying risk has been resolved (e.g., through surgical resection or repair) Patients with active pharyngocutaneous fistula Active fistula The patient has a history of GI perforation and/or fistulae within months prior to enrollment History of gastrointestinal perforation; patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired or has healed, there has been no evidence of fistula for at least months, and patient is deemed to be at low risk of recurrent fistula History of gastrointestinal perforation or fistula in the past months, or while previously on antiangiogenic therapy, unless underlying risk has been resolved (e.g., through surgical resection or repair) History of rectal fistula History of abdominal fistula or gastrointestinal perforation =< months prior to treatment with study drugs History of abdominal fistula or gastrointestinal perforation =< months prior to treatment with study drugs History of abdominal fistula or gastrointestinal perforation within months prior to day Patient is diagnosed with benign or malignant stricture, fistula, perforation, or leak Gastrointestinal (GI) perforation/fistula History of abdominal fistula or gastrointestinal perforation within months prior to day of FOLFIRI + bevacizumab initiation History of abdominal fistula or gastrointestinal perforation within months prior to randomization History of gastrointestinal perforation and /or fistula or aorto-esophageal fistula within months prior to randomization Subjects with evidence of bladder perforation during diagnostic cystoscopy may be treated if perforation has resolved prior to dosing. History of gastrointestinal perforation, abscess or fistula Has a history of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past years; subjects with ulceration, bleeding or perforation in the lower bowel are not excluded Patients with clinically significant gastrointestinal abnormalities including, but not limited to:\r\n* Clinically significant signs and/or symptoms of bowel obstruction within months prior to starting treatment\r\n* History of intra-abdominal abscess within months prior to starting treatment\r\n* History of gastrointestinal (GI) perforation within months prior to starting treatment\r\n* Evidence of abdominal fistula within months prior to starting treatment; history of abdominal fistula will be considered eligible if the fistula was surgically repaired, and there has been no evidence of fistula for at least months prior to starting treatment, and patient is deemed to be at low risk of recurrent fistula History of gastrointestinal perforation; patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired or has healed, there has been no evidence of fistula for at least months, and patient is deemed to be at low risk of recurrent fistula History of abdominal fistula or gastrointestinal perforation within months prior to Day Patients at significant risk for GI perforation or fistula The participant has a history of gastrointestinal perforation or fistula within months. History of abdominal fistula or gastrointestinal perforation at any point within months prior to day of study drug, unless surgically repaired Patients may not have a prior history of GI perforation/fistula (within months of first dose of protocol therapy) or risk factors of perforation History of gastrointestinal perforation or fistula in the past months, or while previously on antiangiogenic therapy, unless underlying risk has been resolved (e.g., through surgical resection or repair) No history of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past years; patients with ulceration, bleeding or perforation in the lower bowel are NOT excluded History of gastrointestinal perforation or fistula in the past months, or while previously on antiangiogenic therapy, unless underlying risk has been resolved (e.g., through surgical resection or repair) have a history of GI perforation and/or fistulae within months prior to enrollment Have a history of gastrointestinal perforation and/or fistulae within months prior to randomization. Have a history of gastrointestinal perforation and/or fistulae within months prior to randomization. History of abdominal fistula or gastrointestinal perforation at any point within months prior to day of study drug, unless surgically repaired Patients with a history of abdominal fistula or gastrointestinal (GI) perforation within months prior to registration are not eligible History of GI perforation. Patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired, there has been no evidence of fistula for at least months prior to starting treatment, and patient is deemed to be at low risk of recurrent fistula History of known risks factors for bowel perforation Have a history of gastrointestinal perforation and/or fistula within months prior to enrollment. The participant has a history of gastrointestinal perforation or fistula within months prior to randomization. Participants may not have had history of abdominal fistula or gastrointestinal perforation; patients with a history of abdominal fistula will be considered eligible if the fistula has healed or was surgically repaired, there has been no evidence of fistula for at least months, and patient is deemed to be at low risk of recurrent fistula History of gastrointestinal perforation =< months prior to randomization History of upper gastrointestinal bleeding, ulceration, or perforation within months prior to the first dose of study drug Prior history of bowel perforation History of gastrointestinal (GI) perforation within years or patient has a current or prior intestinal fistula History of abdominal fistula or gastrointestinal perforation within months prior to day History of abdominal fistula or gastrointestinal perforation within months prior to day - Ongoing bowel perforation or presence of bowel fistula or abscess within months of registration History of upper gastrointestinal bleeding, ulceration, or perforation within months prior to the first dose of study drug. History of upper gastrointestinal bleeding, ulceration, or perforation within months prior to the first dose of protocol therapy History of gastrointestinal perforation and/or fistulae within months prior to course day (CD) History of abdominal fistula or gastrointestinal perforation =< months prior to treatment with study drugs History of abdominal fistula or gastrointestinal perforation within months prior to Day . History of upper GI bleeding, ulceration, or perforation within months prior to the first dose of study drug. History of upper gastrointestinal bleeding, ulceration, or perforation within months. Have a history of GI perforation and/or fistulae within months prior to receiving study drugs. History of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past years; patients with ulceration, bleeding or perforation in the lower bowel are not excluded History of abdominal fistula or gastrointestinal perforation History of prior gastrointestinal perforation History of complicated diverticulitis, including fistulae, abscess formation or gastrointestinal (GI) perforation History of a gastrointestinal perforation History of abdominal fistula or gastrointestinal perforation within months prior to day Gastrointestinal perforation or fistulae within months prior to randomization. Patients with active gastrointestinal disorders, those requiring procedures that pre-dispose to gastrointestinal (GI) perforation, those with a history of transmural inflammatory conditions, and/or history of gastrointestinal ulcers, strictures, obstructions, fistulae, and/or abscess will be excluded from the study due to the risk of serious and sometimes fatal gastrointestinal perforation Patients at risk for GI perforation. History of gastrointestinal perforation or fistula in the past months, or while previously on antiangiogenic therapy, unless underlying risk has been resolved